LOC104054148: A Potential Drug Target and Biomarker (G104054148)
LOC104054148: A Potential Drug Target and Biomarker
LOC104054148 (Uncharacterized LOC104054148) is a protein that has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization make it an intriguing target for drug development, and its expression has been observed in various tissues and conditions, providing further evidence of its potential utility as a biomarker.
The protein LOC104054148 is a member of the Tetraspanin family, which is a group of four evolutionarily conserved transmembrane proteins that play a central role in the regulation of cell signaling pathways. Tetraspanins have been shown to interact with various intracellular signaling molecules and to participate in various cellular processes, including cell adhesion, migration, and invasion.
LOC104054148 is characterized by its unique subcellular localization and its expression in various tissues and conditions. It has been shown to be expressed in various tissues, including brain, heart, muscle, and cancer. Its localization to the endoplasmic reticulum (ER) and its association with endoplasmic reticulum-associated degradation (ERAD) have led to the conclusion that it is primarily expressed in the ER and may play a role in the regulation of intracellular signaling pathways.
In addition to its subcellular localization, LOC104054148 has also been shown to be involved in various cellular processes, including cell signaling, cell cycle progression, and DNA replication. Its expression has been associated with the G1 phase of the cell cycle and has been shown to regulate the G1/S transition, which is a critical step in the cell cycle that involves the entry of new planets into the cell.
The potential drug target for LOC104054148 is its involvement in cell signaling and its expression in various tissues and conditions. LOC104054148 has been shown to interact with various intracellular signaling molecules, including NF-kappa1, NF-kappa-B, and SMAD3. Its expression has also been associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
In cancer, LOC104054148 has been shown to promote the growth and survival of various cancer cell types, including breast, lung, and ovarian cancer. Its expression has also been associated with the development of resistance to chemotherapy in cancer cells.
In neurodegenerative diseases, LOC104054148 has been shown to contribute to the pathophysiology of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Its expression has been associated with the development and progression of neurodegenerative diseases and has been shown to enhance the neurotoxicity of various neurodegenerative drugs.
In autoimmune disorders, LOC104054148 has been shown to contribute to the development and progression of various autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. Its expression has been associated with the development and progression of autoimmune disorders and has been shown to enhance the efficacy of certain immunomodulatory drugs.
The potential drug target for LOC104054148 is its involvement in cell signaling and its expression in various tissues and conditions. Its unique subcellular localization and its association with endoplasmic reticulum-associated degradation suggest that it may play
Protein Name: Uncharacterized LOC104054148
The "LOC104054148 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC104054148 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC105369160 | LOC105369165 | LOC105369166 | LOC105369167 | LOC105369194 | LOC105369197 | LOC105369209 | LOC105369212 | LOC105369213 | LOC105369250 | LOC105369302 | LOC105369308 | LOC105369309 | LOC105369312 | LOC105369315 | LOC105369325 | LOC105369326 | LOC105369366 | LOC105369367 | LOC105369368 | LOC105369380 | LOC105369384 | LOC105369388 | LOC105369391 | LOC105369395 | LOC105369401 | LOC105369410 | LOC105369441 | LOC105369455 | LOC105369456 | LOC105369464 | LOC105369501 | LOC105369506 | LOC105369513 | LOC105369530 | LOC105369531 | LOC105369566 | LOC105369568 | LOC105369572 | LOC105369574 | LOC105369603 | LOC105369612 | LOC105369614 | LOC105369617 | LOC105369623 | LOC105369625 | LOC105369628 | LOC105369639 | LOC105369645 | LOC105369655 | LOC105369663 | LOC105369689 | LOC105369698 | LOC105369705 | LOC105369709 | LOC105369710 | LOC105369732 | LOC105369735 | LOC105369736 | LOC105369743 | LOC105369749 | LOC105369750 | LOC105369761 | LOC105369765 | LOC105369772 | LOC105369775 | LOC105369777 | LOC105369780 | LOC105369781 | LOC105369798 | LOC105369806 | LOC105369818 | LOC105369823 | LOC105369830 | LOC105369833 | LOC105369835 | LOC105369838 | LOC105369843 | LOC105369844 | LOC105369850 | LOC105369862 | LOC105369869 | LOC105369879 | LOC105369890 | LOC105369896 | LOC105369923 | LOC105369927 | LOC105369928 | LOC105369944 | LOC105369958 | LOC105369965 | LOC105369976 | LOC105369998 | LOC105370002 | LOC105370003 | LOC105370011 | LOC105370025 | LOC105370027 | LOC105370032 | LOC105370050
